Assessment of VX-121/Tezacaftor/Deutivacaftor in participants with cystic fibrosis aged 1–11 years
Summary description of the study
This is a multicenter phase III study to assess the safety, tolerability, and efficacy of the DK therapy VX-121/TEZ/D-IVA in participants with cystic fibrosis aged 1 to 11 years. The study lasts 24 or 28 weeks - During this time, 11 clinic visits will take place, each lasting between 2.5 and 5.5 hours.
(BASEC)
Intervention under investigation
During the treatment period, all participants will receive VX-121/TEZ/D-IVA for approximately 24 weeks in addition to their regular cystic fibrosis medication.
(BASEC)
Disease under investigation
Cystic fibrosis
(BASEC)
- Patients aged between 6 and 11 years with a confirmed diagnosis of CF - Body weight must be between the 5th and 95th percentile - Patients must have at least one TCR mutation (including F508del) in the CFTR gene (BASEC)
Exclusion criteria
- Anamnesis of disease that presents an additional risk to the patient or could distort study results - Significant deviations of laboratory values from the norm - Anamnesis of intolerance to a substance of the study medication (BASEC)
Trial sites
Bern, Zurich
(BASEC)
Sponsor
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (CH) GmbH
(BASEC)
Contact
Contact Person Switzerland
Prof. Dr. Alexander Möller
+41 44 249 49 49
alexander.moeller@clutterkispi.uzh.chUnversitäts-Kinderspital Zürich Lenggstrasse 30 8008 Zürich
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Zurich
(BASEC)
Date of authorisation
29.11.2022
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX‑121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available